Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players

27 de julho de 2026 atualizado por: Jakub Krejci, Palacky University

Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial

The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:

  • Does hydrogen-rich water improve autonomic recovery after functional overreaching?
  • Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?

Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:

  • Complete a training cycle including normal training, functional overreaching, and tapering.
  • Consume hydrogen-rich or placebo water daily during the one-week tapering period.
  • Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.

The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.

Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.

Tipo de estudo

Intervencional

Inscrição (Estimado)

30

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

  • Tcheca
      • Olomouc, Tcheca, 77111
        • Recrutamento
        • Palacky University, Faculty of Physical Culture
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Competitive male basketball players.
  • Signed informed consent.
  • Completion of entry medical and laboratory screening.

Exclusion Criteria:

  • Acute injury or infection.
  • History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
  • Use of medication affecting recovery markers or study results.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Hydrogen-rich water
Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.
Suplemento dietético: Hydrogen-rich water
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
Outros nomes:
  • Tirtan generator (Nutristamina, Ostrava, Czech Republic)
Comparador de Placebo: Placebo water
Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.
Suplemento dietético: Placebo water
Tap water without molecular hydrogen.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
RMSSD
Prazo: One-week change between post-overreaching and post-taper.
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
One-week change between post-overreaching and post-taper.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Creatine kinase
Prazo: One-week change between post-overreaching and post-taper.
Blood creatine kinase concentration is used as a marker of muscle damage.
One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
Prazo: One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
One-week change between post-overreaching and post-taper.
Cortisol
Prazo: One-week change between post-overreaching and post-taper.
Blood cortisol concentration is used as a marker of physiological stress response.
One-week change between post-overreaching and post-taper.
Testosterone
Prazo: One-week change between post-overreaching and post-taper.
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
One-week change between post-overreaching and post-taper.
Urea
Prazo: One-week change between post-overreaching and post-taper.
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
One-week change between post-overreaching and post-taper.
Leukocytes
Prazo: One-week change between post-overreaching and post-taper.
Blood leukocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Lymphocytes
Prazo: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Neutrophils
Prazo: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of imflammatory response to training.
One-week change between post-overreaching and post-taper.
Reactive strength index
Prazo: One-week change between post-overreaching and post-taper.
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
One-week change between post-overreaching and post-taper.
Hangrip test
Prazo: One-week change between post-overreaching and post-taper.
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
One-week change between post-overreaching and post-taper.
20-m sprint
Prazo: One-week change between post-overreaching and post-taper.
20-m sprint test is used to assess linear speed.
One-week change between post-overreaching and post-taper.
Repeated sprint
Prazo: One-week change between post-overreaching and post-taper.
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
One-week change between post-overreaching and post-taper.
Agility T-test
Prazo: One-week change between post-overreaching and post-taper.
Agility T-test is used to assess planned change-of-direction performance.
One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
Prazo: One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test is used to assess basketball-specific performance.
One-week change between post-overreaching and post-taper.
Muscle soreness
Prazo: One-week change between post-overreaching and post-taper.
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
One-week change between post-overreaching and post-taper.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Palacky University

Investigadores

  • Investigador principal: Jan Kvas, Palacky University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de julho de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

15 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de julho de 2026

Primeira postagem (Real)

20 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • FTK_2026_13

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All IPD that underlie results in a publication.

Prazo de Compartilhamento de IPD

Beginning 1 month after the publication of results with no end date.

Critérios de acesso de compartilhamento IPD

Anonymized IPD will be uploaded to an open-access data repository.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever